New Drugs for Targeted Radionuclide Therapy in Metastatic Prostate Cancer
Author:
Publisher
Elsevier BV
Reference9 articles.
1. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer;Sartor;N Engl J Med,2021
2. A single-arm, low-dose, prospective study of 177Lu-EB-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer;Wang;J Nucl Med,2023
3. A phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of [177Lu]Lu-LNC1003 in patients with metastatic castration-resistant prostate cancer;Zang;Eur J Nucl Med Mol Imaging,2024
4. Shin D, Ha S, O JH, et al. A single dose of novel PSMA-targeting radiopharmaceutical agent [177Lu]Ludotadipep for patients with metastatic castration-resistant prostate cancer: phase I clinical trial. Cancers 2022;14:6225.
5. Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC;Kramer;Eur J Nucl Med Mol Imaging,2021
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3